# ORMP catalysts: ORAMED PHARMACEUTICALS INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ormp/catalysts

> ORAMED PHARMACEUTICALS INC. (ORMP) has 2 upcoming catalysts. The next is the ormd-0801 8 mg topline data readout, Apr to Jul 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ORAMED PHARMACEUTICALS INC. |
| Ticker | ORMP (Nasdaq) |
| SEC CIK | 1176309 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ormp |

## Cash runway

Cash $38.0M as of 2026-06-30; quarterly burn $200K; about 569.4 months of runway at that rate (XBRL company facts, accession 0001213900-26-087361).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 12, 2023 | [ORAMED PHARMACEUTICALS INC. topline data readout](https://sec-api.dev/companies/ormp/catalysts) | ORMP |  | completed, missed | "On January 12, 2023, we announced top-line results from the phase 3 trial of our oral insulin capsule, which did not meet its primary or secondary endpoints, and indicated that we expect to discontinue oral insulin clinical activities for T2D. At present, following the results of the ORA-D-013-1 Phase 3 trial, we conducted a comprehensive analysis of the data and found that subpopulations of patients with pooled specific parameters responded well to oral insulin." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm)) |
| November 17, 2025 | [ORAMED PHARMACEUTICALS INC. earnings report](https://sec-api.dev/companies/ormp/catalysts) | ORMP |  | completed | "Oramed Reports Fiscal Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1176309/000121390025111310/ea026594901ex99-1_oramed.htm)) |
| late 2026 | [ORAMED PHARMACEUTICALS INC. topline data readout](https://sec-api.dev/companies/ormp/catalysts) | ORMP |  | scheduled | "Alpha Tau has begun submitting modules of its Modular Pre-Market Approval (PMA) application to the FDA and has finished treating patients in its ReSTART pivotal trial, with top-line data from the trial expected in late 2026 or early 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1176309/000121390026119064/ea0311557-10q_oramed.htm)) |
| Apr to Jul 2027 | [Ormd-0801 8 mg topline data readout](https://sec-api.dev/pdufa/ormd-0801) | ORMP | Type 2 Diabetes Mellitus | scheduled | "NCT06731075 (A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-04-25 (ESTIMATED); Lead Sponsor Oramed, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06731075)) |
| April 2027 | [Ormd-0801 8 mg primary completion](https://sec-api.dev/pdufa/ormd-0801) | ORMP | Type 2 Diabetes Mellitus | scheduled | "NCT06731075 (A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-04-25 (ESTIMATED); Lead Sponsor Oramed, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06731075)) |

## Drugs

- [Ormd-0801 8 mg](https://sec-api.dev/pdufa/ormd-0801): Type 2 Diabetes Mellitus

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ormp/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ORMP catalysts: ORAMED PHARMACEUTICALS INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ormp/catalysts

```bibtex
@misc{secapidev_companies_ormp_catalysts_20261116,
  title        = {ORMP catalysts: ORAMED PHARMACEUTICALS INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ormp/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ormp_catalysts_20261116","title":"ORMP catalysts: ORAMED PHARMACEUTICALS INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ormp/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
